A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the long-term safety and tolerability of elexacaftor
(ELX)/tezacaftor (TEZ)/ ivacaftor (IVA) triple combination (TC) in subjects with cystic
fibrosis (CF) who are homozygous for F508del.